The unfinished business of primary biliary cirrhosis

Carlo Selmi, Massimo Zuin, M. Eric Gershwin

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

In nearly every multifactorial human disease, there are three periods that characterize our understanding and definition. First, there is a period in which there is rapid accumulation of descriptive data. Second, there is a longer and slower period as information is obtained that redefines and expands basic and clinical knowledge that lacks the final and important area of understanding aetiology and therapeutic intervention. Third, which is much less common for most diseases, is the vigorous definition of pathobiology and treatment. These phases are well illustrated by our current understanding of primary biliary cirrhosis (PBC). The term PBC was first used nearly 60 years ago and for the first 40 or so years, the primary research efforts were directed at clinical definitions and pathology. Subsequently, with the advent of molecular biology, there began a rigorous dissection of the immune response and, in particular, a better understanding of anti-mitochondrial antibodies. These efforts have greatly helped in our understanding of not only the effector mechanisms of disease, but also the uniqueness of the primary target tissue, biliary epithelium. However, this research has still not led to successful translation for specific therapy.

Original languageEnglish (US)
Pages (from-to)451-460
Number of pages10
JournalJournal of Hepatology
Volume49
Issue number3
DOIs
StatePublished - Sep 2008

Fingerprint

Biliary Liver Cirrhosis
Clinical Pathology
Research
Dissection
Molecular Biology
Anti-Idiotypic Antibodies
Epithelium
Therapeutics

Keywords

  • Anti-mitochondrial antibodies
  • Anti-nuclear antibodies
  • Genetic bases of PBC
  • Primary biliary cirrhosis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

The unfinished business of primary biliary cirrhosis. / Selmi, Carlo; Zuin, Massimo; Gershwin, M. Eric.

In: Journal of Hepatology, Vol. 49, No. 3, 09.2008, p. 451-460.

Research output: Contribution to journalArticle

Selmi, Carlo ; Zuin, Massimo ; Gershwin, M. Eric. / The unfinished business of primary biliary cirrhosis. In: Journal of Hepatology. 2008 ; Vol. 49, No. 3. pp. 451-460.
@article{1e657033f1864317a6e4a27931721a82,
title = "The unfinished business of primary biliary cirrhosis",
abstract = "In nearly every multifactorial human disease, there are three periods that characterize our understanding and definition. First, there is a period in which there is rapid accumulation of descriptive data. Second, there is a longer and slower period as information is obtained that redefines and expands basic and clinical knowledge that lacks the final and important area of understanding aetiology and therapeutic intervention. Third, which is much less common for most diseases, is the vigorous definition of pathobiology and treatment. These phases are well illustrated by our current understanding of primary biliary cirrhosis (PBC). The term PBC was first used nearly 60 years ago and for the first 40 or so years, the primary research efforts were directed at clinical definitions and pathology. Subsequently, with the advent of molecular biology, there began a rigorous dissection of the immune response and, in particular, a better understanding of anti-mitochondrial antibodies. These efforts have greatly helped in our understanding of not only the effector mechanisms of disease, but also the uniqueness of the primary target tissue, biliary epithelium. However, this research has still not led to successful translation for specific therapy.",
keywords = "Anti-mitochondrial antibodies, Anti-nuclear antibodies, Genetic bases of PBC, Primary biliary cirrhosis",
author = "Carlo Selmi and Massimo Zuin and Gershwin, {M. Eric}",
year = "2008",
month = "9",
doi = "10.1016/j.jhep.2008.06.006",
language = "English (US)",
volume = "49",
pages = "451--460",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - The unfinished business of primary biliary cirrhosis

AU - Selmi, Carlo

AU - Zuin, Massimo

AU - Gershwin, M. Eric

PY - 2008/9

Y1 - 2008/9

N2 - In nearly every multifactorial human disease, there are three periods that characterize our understanding and definition. First, there is a period in which there is rapid accumulation of descriptive data. Second, there is a longer and slower period as information is obtained that redefines and expands basic and clinical knowledge that lacks the final and important area of understanding aetiology and therapeutic intervention. Third, which is much less common for most diseases, is the vigorous definition of pathobiology and treatment. These phases are well illustrated by our current understanding of primary biliary cirrhosis (PBC). The term PBC was first used nearly 60 years ago and for the first 40 or so years, the primary research efforts were directed at clinical definitions and pathology. Subsequently, with the advent of molecular biology, there began a rigorous dissection of the immune response and, in particular, a better understanding of anti-mitochondrial antibodies. These efforts have greatly helped in our understanding of not only the effector mechanisms of disease, but also the uniqueness of the primary target tissue, biliary epithelium. However, this research has still not led to successful translation for specific therapy.

AB - In nearly every multifactorial human disease, there are three periods that characterize our understanding and definition. First, there is a period in which there is rapid accumulation of descriptive data. Second, there is a longer and slower period as information is obtained that redefines and expands basic and clinical knowledge that lacks the final and important area of understanding aetiology and therapeutic intervention. Third, which is much less common for most diseases, is the vigorous definition of pathobiology and treatment. These phases are well illustrated by our current understanding of primary biliary cirrhosis (PBC). The term PBC was first used nearly 60 years ago and for the first 40 or so years, the primary research efforts were directed at clinical definitions and pathology. Subsequently, with the advent of molecular biology, there began a rigorous dissection of the immune response and, in particular, a better understanding of anti-mitochondrial antibodies. These efforts have greatly helped in our understanding of not only the effector mechanisms of disease, but also the uniqueness of the primary target tissue, biliary epithelium. However, this research has still not led to successful translation for specific therapy.

KW - Anti-mitochondrial antibodies

KW - Anti-nuclear antibodies

KW - Genetic bases of PBC

KW - Primary biliary cirrhosis

UR - http://www.scopus.com/inward/record.url?scp=48449102199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48449102199&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2008.06.006

DO - 10.1016/j.jhep.2008.06.006

M3 - Article

C2 - 18640737

AN - SCOPUS:48449102199

VL - 49

SP - 451

EP - 460

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 3

ER -